Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT02675231. IPD Sharing: YES. Countries: 14. Publications: 2.
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
ClinicalTrials.gov study NCT01441596. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
ClinicalTrials.gov study NCT00432172. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00320385. IPD Sharing: Not stated. Countries: 13. Publications: 2.
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT04975308. IPD Sharing: YES. Countries: 22. Publications: 1.
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
ClinicalTrials.gov study NCT02032823. IPD Sharing: YES. Countries: 24. Publications: 3.
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
ClinicalTrials.gov study NCT04757363. IPD Sharing: YES. Countries: 1. Publications: 1.
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
ClinicalTrials.gov study NCT02499146. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
ClinicalTrials.gov study NCT04539938. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT00929240. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
ClinicalTrials.gov study NCT01769508. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
ClinicalTrials.gov study NCT03025880. IPD Sharing: NO. Countries: 1. Publications: 2.
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
ClinicalTrials.gov study NCT01325207. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
ClinicalTrials.gov study NCT03054363. IPD Sharing: NO. Countries: 1. Publications: 2.
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
ClinicalTrials.gov study NCT02600923. IPD Sharing: YES. Countries: 4. Publications: 1.
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
ClinicalTrials.gov study NCT01875367. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
ClinicalTrials.gov study NCT04082364. IPD Sharing: NO. Countries: 9. Publications: 1.
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
ClinicalTrials.gov study NCT01268150. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00951665. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Met
ClinicalTrials.gov study NCT03653507. IPD Sharing: YES. Countries: 18. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.